Show simple item record

dc.contributor.authorMcMaster, M
dc.contributor.authorKim, S
dc.contributor.authorClare, L
dc.contributor.authorTorres, SJ
dc.contributor.authorD este, C
dc.contributor.authorAnstey, KJ
dc.date.accessioned2018-12-20T09:47:26Z
dc.date.issued2018-11-21
dc.description.abstractBackground: With no cure for dementia and the number of people living with the condition predicted to rapidly rise, there is an urgent need for dementia risk reduction and prevention interventions. Modifiable lifestyle risk factors have been identified as playing a major role in the development of dementia; hence, interventions addressing these risk factors represent a significant opportunity to reduce the number of people developing dementia. Relatively few interventions have been trialed in older participants with cognitive decline (secondary prevention). Objectives: This study evaluates the efficacy and feasibility of a multidomain lifestyle risk reduction intervention for people with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Methods: This study is an 8-week, two-arm, single-blind, randomized controlled trial (RCT) of a lifestyle modification program to reduce dementia risk. The active control group receives the following four online educational modules: dementia literacy and lifestyle risk, Mediterranean diet (MeDi), cognitive engagement and physical activity. The intervention group also completes the same educational modules but receives additional practical components including sessions with a dietitian, online brain training and sessions with an exercise physiologist to assist with lifestyle modification. Results: Primary outcome measures are cognition (The Alzheimer’s Disease Assessment Scale-Cognitive-Plus [ADAS-Cog-Plus]) and a composite lifestyle risk factor score for Alzheimer’s disease (Australian National University – Alzheimer’s Disease Risk Index [ANU-ADRI]). Secondary outcome measures are motivation to change lifestyle (Motivation to Change Lifestyle and Health Behaviour for Dementia Risk Reduction [MCLHB-DRR]) and health-related quality of life (36-item Short Form Health Survey [SF-36]). Feasibility will be determined through adherence to diet (Mediterranean Diet Adherence Screener [MEDAS] and Australian Recommended Food Score [ARFS]), cognitive engagement (BrainHQ-derived statistics) and physical activity interventions (physical activity calendars). Outcomes are measured at baseline, immediately post-intervention and at 3-and 6-month follow-up by researchers blind to group allocation. Discussion: If successful and feasible, secondary prevention lifestyle interventions could provide a targeted, cost-effective way to reduce the number of people with cognitive decline going on to develop Alzheimer’s disease (AD) and other dementias.en_GB
dc.description.sponsorshipDementia Australia Research Foundationen_GB
dc.description.sponsorshipAustralian National Universityen_GB
dc.description.sponsorshipDementia Collaborative Research Centreen_GB
dc.description.sponsorshipNHMRC Centre for Research Excellence in Cognitive Health, the Australian National Universityen_GB
dc.description.sponsorshipNeuroscience Research Australia, University of New South Walesen_GB
dc.description.sponsorshipRoyal Commonwealth Societyen_GB
dc.identifier.citationVol. 13, pp. 2397 - 2406en_GB
dc.identifier.doi10.2147/CIA.S182046
dc.identifier.urihttp://hdl.handle.net/10871/35220
dc.language.isoenen_GB
dc.publisherDove Medical Press for Society for Applied Research in Aging (SARA)en_GB
dc.rights© 2018 McMaster et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.en_GB
dc.subjectdementia preventionen_GB
dc.subjectdementia risk reductionen_GB
dc.subjectsecondary preventionen_GB
dc.subjectAlzheimer’s diseaseen_GB
dc.subjectsubjective cognitive declineen_GB
dc.subjectmild cognitive impairmenten_GB
dc.subjectmultidomain lifestyle interventionen_GB
dc.titleBody, brain, life for cognitive decline (BBL-CD): Protocol for a multidomain dementia risk reduction randomized controlled trial for subjective cognitive decline and mild cognitive impairmenten_GB
dc.typeArticleen_GB
dc.date.available2018-12-20T09:47:26Z
dc.identifier.issn1176-9092
dc.descriptionThis is the final version. Available from Dove Medical Press via the DOI in this record. en_GB
dc.identifier.journalClinical Interventions in Agingen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/en_GB
dcterms.dateAccepted2018-09-22
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2018-11-21
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2018-12-20T09:32:29Z
refterms.versionFCDVoR
refterms.dateFOA2018-12-20T09:47:30Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2018 McMaster et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Except where otherwise noted, this item's licence is described as © 2018 McMaster et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.